Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, Pyrosequencing in Cross-Licensing Deal

NEW YORK, March 12 -- Genetic Technologies of Melbourne, Australia, and Pyrosequencing of Uppsala, Sweden, today announced a cross-licensing agreement the two companies are valuing at $2.5 million.


Pyrosequencing will pay Genetic Technologies a fee of $500,000 and royalties for a non-exclusive license to Genetic Technologies' non-coding DNA analysis and mapping patents. Genetic Technologies will install three Pyrosequencing instruments in Australia, and gain access to intellectual property for use in Australia and New Zealand.


The companies will collaborate to develop gene-based assays based on the Pyrosequencing platform.


In a statement, the companies said that cash payments, instruments, reagents, assay design services, intellectual property and royalties is estimated to be worth $2.5 million.


Genetic Technologies will apply the technology to its genetics diagnostics business, and its cacncer-susceptibility testing facility being established in Melbourne.



The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.